Product review · Updated September 30, 2026
Peter Thomas Roth Peptide Skinjection review: complex percentages and separate cohorts
The serum's advertised mixtures, complete other-peptide list and three different evidence groups examined within their stated scopes.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Peter Thomas Roth's Peptide Skinjection Amplified Wrinkle-Fix Serum places 19% Peptide Complex and 10% Argirelox near claims about expression lines. Its page also mentions several peptide solutions and three different study groups. The figures look comparable at first glance, but they refer to mixtures, reported agreement and separate evidence settings rather than one verified active-content or outcome measure.
We reviewed the official serum record for SKU1501069 captured September 30, 2026. The complete list names other peptides and no copper. Skinjection is product branding, not evidence that a topical serum is equivalent to an injection. We did not use the serum, inspect a batch assay or read the full underlying study reports.
In this article
The headline names two advertised mixtures
The official description presents a 19% Peptide Complex and 10% Argirelox within a non-invasive topical serum. The ingredient-highlight section repeats those names. These are the manufacturer's mixture labels, rather than independent analytical results obtained by this publication. Headline and highlights.
The record does not identify the pure amount of every peptide within each named material. A larger printed percentage therefore cannot be assumed to mean more of the same ingredient found in another formula. The grade-and-purity guide supplies background for distinguishing a material specification from an amount claim and its verification. That distinction is necessary before any numerical comparison of the serum could be meaningful.
The smaller figures explicitly describe solutions
The page names amplified peptide solutions of 2% Matrixyl Morphomics, 5% Argireline Amplified and 2% Matrixyl Synthe'6, alongside the 10% Argirelox statement. The word solutions matters: the retained text does not establish that those figures are pure peptide mass fractions in the finished serum. Solution wording.
We preserve the listed figures without reverse-engineering a formula or resolving the marketing arithmetic through assumptions. A constituent specification and finished-product assay would answer questions the highlight panel leaves open. The Prequel review offers another topic for mixture-versus-ingredient reading. Its blend descriptions neither define these trade materials nor validate their advertised amounts.
93% belongs to a consumer-perception statement
The serum page describes a six-week consumer-perception study involving 28 women aged 37 to 64. It reports that 93% agreed no new lines had formed. This is a stated share agreeing with a proposition, not a 93% reduction in wrinkles and not an ingredient concentration. Consumer-study summary.
We do not independently verify that agreement or infer the size of any measured change. The retained excerpt does not supply the full questionnaire, comparator or analysis. The firmness-claims guide provides background for separating a person's reported impression from a measured endpoint. Keeping the assessment type visible prevents the percentage from acquiring a stronger meaning than the brand's summary supports.
The clinically measured group has a different count
A separate footnote identifies a four-week clinically measured study on 53 women aged 37 to 64. That count, assessment description and timepoint differ from the consumer-perception summary. The page's compressed evidence presentation does not allow us to merge the groups or treat the measured study as a verification of every consumer statement. Measured-study footnote.
The full report was not inspected, so the measurement tool and detailed analysis remain unresolved here. The study-endpoint guide offers context for matching claims to their own endpoints. The presence of a measured-study footnote is useful information, but it cannot provide missing methods or turn every nearby benefit phrase into an independently reproduced result.
The neurotoxin-related study concerns another setting
The third summary describes 22 women, with an average age of 51, in a setting involving neurotoxin injections and a 10% Argirelox peptide solution over six months. The reviewed footnote does not establish that the tested solution was the complete current serum. It also differs from the other two participant groups. Separate study setting.
That study setting does not demonstrate that the finished serum substitutes for an injection or establishes a procedure plan. The Paula's Choice review is another navigation topic for separate study summaries, not evidence for this serum. Neither pooling the cohorts nor transferring a solution finding to the finished mixture would be supported by the retained record.
The complete declaration gives a narrower identity
The captured list includes Acetyl Hexapeptide-8, Pentapeptide-18, N-Prolyl Palmitoyl Tripeptide-56 Acetate and Palmitoyl Tripeptide-38 among many other ingredients. No copper ingredient is named. These identities explain the Other peptides category; they do not establish the individual amounts or match a study solution by themselves. Complete serum declaration.
The review concerns this serum record, not a neighboring cream or an unspecified family of products. No physical label or finished batch was examined. The public-source comparison provides a broader reading topic for how much a declaration and study summary actually identify. A complete list is valuable evidence of named composition without becoming a quantitative laboratory report.
Three evidence groups do not form one efficacy number
The record contains advertised solution and complex percentages, a 28-woman perception summary, a 53-woman measured-study footnote and a distinct 22-woman solution-and-procedure setting. Each has its own scope. The selected page supplies no basis for adding participants, calculating a combined response rate or assigning the current serum an injection-equivalent outcome. Official evidence record.
The useful unresolved question is what each full report and material specification establishes for this exact finished serum. Until that match is available, we retain the figures as attributed claims and separate summaries. This other-peptide comparator is not a copper product in the reviewed declaration, and its marketing name provides no personal treatment recommendation.
Sources behind this reading
- Peter Thomas Roth: Peptide Skinjection Amplified Wrinkle-Fix Serum ↗Exact serum SKU, complete non-copper list, solution-complex claims and three distinct study summaries · Checked September 30, 2026